CN111758669B - Construction method and application of animal model with yang-deficiency constipation - Google Patents
Construction method and application of animal model with yang-deficiency constipation Download PDFInfo
- Publication number
- CN111758669B CN111758669B CN202010685318.3A CN202010685318A CN111758669B CN 111758669 B CN111758669 B CN 111758669B CN 202010685318 A CN202010685318 A CN 202010685318A CN 111758669 B CN111758669 B CN 111758669B
- Authority
- CN
- China
- Prior art keywords
- acetic acid
- acid solution
- yang
- activated carbon
- animal model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 63
- 208000031975 Yang Deficiency Diseases 0.000 title claims abstract description 46
- 238000010171 animal model Methods 0.000 title claims abstract description 44
- 238000010276 construction Methods 0.000 title claims abstract description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 132
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000005457 ice water Substances 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 241000700159 Rattus Species 0.000 claims description 71
- 208000024891 symptom Diseases 0.000 claims description 22
- 210000001072 colon Anatomy 0.000 claims description 21
- 210000001541 thymus gland Anatomy 0.000 claims description 16
- 230000013872 defecation Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 13
- 210000003097 mucus Anatomy 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 230000004054 inflammatory process Effects 0.000 claims description 9
- 210000002175 goblet cell Anatomy 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- 210000002919 epithelial cell Anatomy 0.000 claims description 7
- 206010030113 Oedema Diseases 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 210000002808 connective tissue Anatomy 0.000 claims description 5
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 5
- 235000021590 normal diet Nutrition 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 230000002567 autonomic effect Effects 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 3
- 235000012631 food intake Nutrition 0.000 claims description 3
- 230000037308 hair color Effects 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 241000700157 Rattus norvegicus Species 0.000 claims description 2
- 210000000805 cytoplasm Anatomy 0.000 claims description 2
- 238000003304 gavage Methods 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000001087 myotubule Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 238000011160 research Methods 0.000 abstract description 8
- 238000011156 evaluation Methods 0.000 abstract description 6
- 238000012827 research and development Methods 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 229960000583 acetic acid Drugs 0.000 description 26
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000000465 moulding Methods 0.000 description 16
- 210000003608 fece Anatomy 0.000 description 14
- 239000000052 vinegar Substances 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- 210000000813 small intestine Anatomy 0.000 description 9
- 238000012453 sprague-dawley rat model Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 4
- 210000001187 pylorus Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000004876 tela submucosa Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000003724 hair brightness Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of animal model construction, and provides a construction method and application of a yang-deficiency constipation animal model in order to solve the problems of high mortality, poor reproducibility and the like of the yang-deficiency constipation animal model. Performing intragastric administration on experimental animals for 1-8 weeks by using 1-8% v/v acetic acid solution and 5-50% g/v activated carbon-containing ice-water mixture, wherein the specific administration method comprises the following steps: the first dosage of the acetic acid solution is 0.5-10.0 mL/mouse, then 0.5-10 mL/100g of the acetic acid solution is administered, and after 0.5-8 hours, 0.5-10 mL/100g of the ice-water mixture containing the activated carbon is administered by intragastric administration. The invention provides an animal model of yang-deficiency type constipation with high stability, easy popularization, low mortality, good reproducibility and economic applicability, and provides experimental basis for prescription screening for treating yang-deficiency type constipation, preclinical research and development of medicines, function evaluation, mechanism research and the like, and research and development of functional foods and health-care foods.
Description
Technical Field
The invention belongs to the technical field of animal model construction, and particularly relates to a construction method and application of a yang-deficiency constipation animal model.
Background
Constipation is a common disorder of the digestive tract, and clinically manifested as dry and hard stools, difficult or incomplete defecation, and decreased weight and frequency of stools. According to epidemiological investigation, the incidence rate of constipation in our country is 3% -17%. With the development of modern society and the change of life style and dietary structure, the incidence rate of chronic constipation is on the rise, and has the characteristics of universality, repeatability, age correlation and the like. The non-lethal nature of constipation, however, often results in therapeutic neglect. But constipation is a great hazard, and can lead to the reduction of the life quality of patients, such as neurasthenia, insomnia, dysphoria, halitosis and the like; secondary anorectal diseases, colon cancer, cardiovascular diseases, senile dementia and other diseases are also increased.
The western medicine considers that the constipation is only a clinical symptom and does not belong to independent diseases. In traditional Chinese medicine, constipation is used as an independent disease, the advantages of syndrome differentiation and treatment are exerted, and individualized treatment is carried out on patients.
The traditional Chinese medicine has more than 2000 years of history of treating constipation, and a great deal of theoretical experience is accumulated in practice grope. The book Su Wen ㆍ treatise on the other five zang organs: the sou men is also the five internal organs, even though secret in the heart, lung, liver, spleen and stomach, kidney, etc., it is closely related to spleen and kidney. The theory of su wen ㆍ jue (su wen ㆍ): "faint due to taiyin" can cause abdominal distension, difficulty in eating, vomiting and inability to lie down. "indicate the relationship between constipation and spleen. Su Wen ㆍ Ci malaria records that "kidney malaria is unrestrained, pain in the loins and back, turning, difficulty in urination and defecation, eyes , cold hands and feet", clearly indicates that constipation is related to kidney yang deficiency.
In conclusion, constipation is closely related to the spleen and kidney. Therefore, the yang-deficiency constipation animal model not only accords with the yang-deficiency performance in the theory of traditional Chinese medicine on the syndrome type, but also accords with the scope of difficult defecation and constipation on the disease, and can better simulate the clinical performance of the patients with yang-deficiency constipation in clinic.
As a scientific research guide, animal experiments can make up for the deficiency of clinical research. Therefore, an animal model with good objectivity, recognition and repeatability plays an important role in understanding the pathogenesis, pathophysiological processes and drug development of diseases. At present, although there is experimental research on traditional Chinese medicine syndrome type animal models of yang-deficiency constipation in China, high mortality and poor reproducibility are important defects of the model research.
Disclosure of Invention
The invention provides a construction method and application of a yang-deficiency constipation animal model, aiming at solving the problems of high mortality rate, poor reproducibility and the like of the current yang-deficiency constipation animal model.
The invention is realized by the following technical scheme: a construction method of an animal model of yang-deficiency constipation comprises the steps of performing intragastric lavage on an experimental animal for 1-8 weeks by using 1-8% v/v acetic acid solution and an ice-water mixture containing 5-50% g/v activated carbon, wherein the specific administration method comprises the following steps: the first dosage of the acetic acid solution is 0.5-10.0 mL/piece, then the acetic acid solution is administered according to 0.5-10 mL/100g, after 0.5-8 hours, the ice-water mixture containing the active carbon is administered according to 0.5-10 mL/100g per piece, the intragastric administration time of the acetic acid solution and the active carbon ice-water mixed solution is 1-8 weeks, namely 7-56 days, and the intragastric administration is carried out for 1-7 times per week;
when the experimental animal shows 5 items of the following (1) (2) (3) (4) (5) (6) (7) major symptoms and 3 items of the following (8) (9) (10) (11) minor symptoms, the construction of the rat animal model with yang-deficiency constipation is successful;
the main symptoms are: (1) the anal temperature decreases; (2) the number of the defecation grains is reduced within 12 hours; (3) the defecation time is prolonged; (4) a decrease in the rate of small bowel advancement; (5) the water content of the excrement is reduced; (6) in colon pathological tissue: epithelial cells fall off or local submucosa edema, connective tissues are arranged loosely, cytoplasm is loose and lightly stained, but the intestinal glands of the inherent layer are rich, more goblet cells can be seen, and obvious inflammation is not seen; (7) decreased mucus secretion from the colon;
the secondary symptoms are: (8) the hair color of the rat becomes grey-dark and dull; (9) weight loss; (10) decreased autonomic activity; (11) a decline in thymus index; (12) the food intake is reduced.
The experimental animal is an SPF-grade healthy adult animal, and the adult animal is any one of an SD rat, a Wistar rat, a C57BL/6 mouse, a BALB/C mouse or a Kunming mouse.
The acetic acid concentration is controlled by pH. The pathological specimen is mainly the colon part.
The invention has the following beneficial effects: the existing constipation model with yang deficiency has the defects of unstable model making, high fatality rate and the like. The invention provides the yang-deficiency constipation animal model which is high in stability, easy to popularize, low in mortality rate and economical and applicable, and provides an experimental basis for the preliminary clinical experimental research and the research and development of foods and medicines with the function of improving the yang-deficiency constipation. Provides experimental basis for prescription screening for treating yang deficiency type constipation, preclinical research and development, function evaluation, mechanism research and the like of medicines, and research and development of functional food and health food.
The invention improves the model on the basis of the previous research, and the new model can greatly reduce the death condition of experimental animals and can obviously improve the replication rate of the model. The invention not only can deepen the understanding of the yang deficiency constipation disease, but also can provide a high-level animal model for the research and development of transformed medicine and new drugs.
Drawings
FIG. 1 is a graph showing the anal temperature of a rat after modeling in an example of the present invention;
FIG. 2 is a graph showing the small intestine propulsion rate of each group of rats after modeling in the example of the present invention;
FIG. 3 is an optical microscope photograph of HE staining of colon tissue specimens wherein (a) is a control group (. times.200 times), (b) is a 3% acetic acid group (. times.200 times), (c) is a 5% acetic acid group (. times.200 times) in an example of the present invention;
FIG. 4 is an optical microscope photograph of the AB-PAS staining of a colon tissue specimen in an example of the present invention, wherein a is a control group (. times.200 times), b is a 3% acetic acid group (. times.200 times), c is a 5% acetic acid group (. times.200 times), and d is the amount of mucus in each group;
FIG. 5 is a diagram of stool morphology of various groups of rats after modeling in an example of the present invention;
FIG. 6 is a graph showing the weight gain of rats after modeling according to the example of the present invention;
FIG. 7 is a graph of thymus index of a modeled rat in an example of the present invention;
FIG. 8 is a survival curve diagram of a rat animal model with acetic acid-induced yang-deficiency constipation modeled for 35 days in example 1 of the present invention;
FIG. 9 is a graph showing the survival rate of rats molded with white vinegar for 35 days in comparative example 1.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described below with reference to specific embodiments. It should be understood that the embodiments described herein are merely illustrative of the present invention and that any modification, equivalent replacement, or improvement made without departing from the spirit and principle of the present invention should be included in the protection scope of the present invention.
Example 1: establishment of acetic acid induced yang deficiency type constipation rat animal model
Preparation of the reagent: 3% (v/v) acetic acid solution: adding edible glacial acetic acid solution (CH)3COOH, tianyu food manufacturers (korea)) was added to distilled water at room temperature (about 25 c) and stirred with a glass rod to be well mixed. When the pH value of the solution is 2.53, the acid addition is stopped.
5% (v/v) acetic acid solution: adding edible glacial acetic acid solution (CH)3COOH, tianyu food manufacturers (korea)) was added to distilled water at room temperature (about 25 c) and stirred with a glass rod to be well mixed. When the pH value of the solution is 2.42, the acid addition is stopped.
Activated carbon ice water mixture: 200g of activated carbon powder (Fuchen chemical Co., Ltd.) was added to 1000 mL of ice water to prepare an ice water mixture containing 20% of activated carbon. The activated carbon is uniformly dispersed in the solution by stirring before use.
Experimental animals: SPF-grade male Sprague-Dawley (SD) rats weighing 180-200 g were provided by the laboratory animal technology of Wintolite, Beijing (Certification number: SCXK (Kyoto) 2016-. During the feeding period, food and water are taken freely, 12-hour light/dark alternation is adopted, and the feeding environment is proper in temperature and humidity.
Animal grouping: SD rats are 50, 10 are randomly selected as a control group and 40 are selected as a model group according to a digital random table. Model groups rats were randomly subdivided into 3% (v/v) acetic acid model groups and 5% (v/v) acetic acid model groups of 20 rats each.
The molding method comprises the following steps: and (3) irrigating the stomach with 1-8% (v/v) acetic acid solution and 5-50% (g/v) activated carbon-containing ice-water mixture for 1-8 weeks (7-56 days), and evaluating the established yang-deficiency constipation animal model by adopting an evaluation method combining major symptoms and minor symptoms. The construction of the rat animal model for yang-deficiency constipation was successful when the experimental animals exhibited 5 of the following major symptoms (1) (2) (3) (4) (5) (6) (7) and 3 of the following minor symptoms (8) (9) (10) (11): (1) anal temperature is reduced (2), defecation grain number is reduced by 12 hours, (3) defecation time is prolonged, (4) small intestine propulsion rate is reduced, (5) water content of excrement is reduced, (6) epithelial cells in colon pathological tissues drop off or local submucosa edema is seen, connective tissues are arranged loosely, but inherent layer intestinal glands are rich, more goblet cells are seen, obvious inflammation is not seen, (7) mucus secretion of colon is reduced, (8) rat hair is grayed and dark, weight is reduced, (9) self-activity ability is reduced, (10) thymus index is reduced, (12) food intake is reduced.
The method comprises the following specific steps:
A. the rats in the 3% acetic acid model group were fed a first dose of 5 mL/3% (v/v) acetic acid solution while eating a normal diet, and the rats were gavaged with a 3% (v/v) acetic acid solution at a dose of 1.5 mL/100g the following day, and after 2 hours, each of them was gavaged with 2.5 mL/100g of an activated carbon-ice water mixture containing 20% (g/v) activated carbon, and were fed 3 times per week; for 35 consecutive days.
B. The rats in the 5% acetic acid model group were fed a first 5.0 mL/5% (v/v) acetic acid solution simultaneously with the normal diet, and were gavaged with a 5% (v/v) acetic acid solution at a dose of 1.5 mL/100g the following day, and after 2 hours, each was gavaged with 2.5 mL/100g of an ice-water mixture containing 20% (g/v) activated carbon 3 times a week; for 35 consecutive days.
C. The rats in the control group were given distilled water in an amount equal to that of the model group while eating a normal diet, 3 times per week; for 35 consecutive days.
Evaluation of establishment of rat animal model: the rat model of constipation due to yang deficiency established in the above examples was subjected to the evaluation test of the following items.
First, evaluation of chief complaints
1. And (3) anal temperature measurement: after the molding is finished, the anal temperatures of all mice are measured by an electronic thermometer.
2. Number of defecation granules in 12 hours: on days 0, 7, 14, 21, 28, 35, all rats were placed in metabolic cages to collect the number of feces per rat over 12 hours; normal group rats were observed contemporaneously.
3. Measurement of first-particle black feces excretion time: after the molding was completed, all rats were gavaged with home-made ink (1 mL/100 g), placed in a metabolic cage, and the time from gavage of the ink to the first removal of black feces was observed and recorded.
4. Determination of small intestine propulsion rate: after fasting of the rats for 12 hours, the rats were gavaged with self-prepared ink (1 mL/100 g), and after 30 min, the rats were sacrificed, the entire gastrointestinal tract was removed by laparotomy, and the distance (cm) from the front end of the ink to the pyloric sphincter and the distance (cm) from the pyloric sphincter to the end of the small intestine were measured. The small intestine propulsion rate was calculated as follows.
Small intestine propulsion rate = distance from ink front to pyloric sphincter (cm)/pyloric sphincter to small intestine end (cm) × 100%
5. And (3) measuring the water content of the excrement: after the model building is finished, the rat is placed in a metabolism cage, and fresh excrement of the rat is collected and weighed as wet weight. The feces were dried in an oven at 60 ℃ for 24 hours, and the dry weight of the feces was determined. The fecal water content was calculated as follows.
Stool water content = (stool wet weight-stool dry weight)/stool wet weight × 100%
6. And (3) observing colon pathological tissue morphology: all rats were sacrificed after fasting for 12 hours without water deprivation, and colon tissue specimens (colon tissue was left at a distance of about 2cm from the cecum) were fixed with 10% (v/v) formaldehyde for 24 hours before HE staining. The pathological changes of the mucosa, the lamina propria and the muscular layer and whether inflammation occurs are observed by using an optical microscope.
7. Secretion of mucus in colonic tissue: all rats were sacrificed after fasting for 12 hours without water deprivation, and colon tissue specimens (colon tissue was left at about 2cm from the cecum) were stained with AB-PAS after 10% (v/v) formaldehyde was fixed for 24 hours. The average number of positive cells for analysis of mucus was counted using Image Pro Plus 6.0 software.
Second, observation and determination of secondary symptoms:
1. general observation of yang deficiency signs: after the modeling is finished, all rats are observed for yang deficiency characteristics such as mental state, abdominal distension degree, hair glossiness, body contracture degree, diet condition, excrement form and the like.
2. Weight gain change: rat body weights were measured at 9 am, three times per rat, and recorded as an average. Three body weights were recorded a week.
3. Determination of autonomic activity capacity: on days 0, 7, 14, 21, 28, 35, all rats were placed in an open field laboratory setting of 100 cm x 100 cm, 60cm high. The test was performed for 5 minutes, acclimated for the first 1 minute, and the number of erections and crossing of the rats was recorded for the last 4 minutes.
4. Thymus index: after the model is made, the weights of all rats are counted before the experimental animals are sacrificed, and the thymus is taken out after the sacrifice and the weight of the thymus is recorded. The organ index of the thymus was calculated as follows.
Organ index of thymus = weight of thymus/body weight.
Thirdly, a statistical method: the experimental data in the examples were analyzed using One-way ANOVA in ANOVA, and the results are expressed as mean. + -. standard deviation (` x. + -. SD).
Fourth, experimental results
(I) results of the experiment of the chief complaints
1. Anal temperature: after the molding is finished, compared with a blank group, the anal temperature of the 3% acetic acid group and the anal temperature of the 5% acetic acid group are both reduced remarkably, and the difference has statistical significance (P is less than 0.01). The results are shown in FIG. 1. The anal temperature is close to the deep blood temperature, so that the real body temperature of the rat can be reflected. The result shows that the acetic acid and the activated carbon ice water can obviously reduce the anal temperature of the rat and show the symptom of yang deficiency.
2. Number of 12-hour defecation grains: the results are shown in Table 1. On day 21 of molding, the 12-hour faecal pellet count was significantly reduced in the 5% acetic acid group compared to the blank group, with a statistically significant difference (P < 0.05). On day 28 of molding, the 12-hour faecal pellet count was significantly reduced in the 3% acetic acid group compared to the blank group, with a statistically significant difference (P < 0.05). The results show that after the molding is finished, the constipation group obviously reduces the number of the defecation granules within 12 hours, and the constipation symptom is obvious.
Note: p < 0.05 compared to blank group.
3. Feces transport time: the results are shown in table 2, where the fecal transit times were significantly longer in the 3% and 5% acetate groups compared to the blank group at 14 days of molding, with the difference being statistically significant (P < 0.05). The prolonged fecal transport time of the model group shows that constipation occurs obviously in rats with constipation due to prolonged defecation interval time.
Note: p < 0.001, P < 0.01, P < 0.05 compared to the blank group.
4. Small intestine propulsion rate: as shown in fig. 2, the small intestine propulsion rates of the 3% acetic acid group and the 5% acetic acid group were significantly decreased compared to the control group, and the difference was statistically significant (P < 0.05). The rate of intestinal transit is one of the important indicators of constipation. The intestinal transit rate was decreased in the constipated rats compared to the blank group, indicating insufficient gastrointestinal motility in the constipated rats.
5. Results for stool water content: the results are shown in Table 3. After the molding is finished, compared with a blank group, the moisture content of the feces of the 3% acetic acid group and the feces of the 5% acetic acid group are obviously reduced, and the difference has statistical significance (P is less than 0.05). The moisture content of the feces reflects the degree of dryness of the feces. Compared with the blank group, the water content of the feces of the model group is obviously reduced, which shows that after the model group is made, the water content in the intestinal tract of the rat is reduced, and the difficulty of defecation is increased.
Note: p < 0.01, P < 0.05 compared to blank group.
6. And (3) observing colon pathological tissue morphology: the results are shown in FIG. 3. After the model building is finished, the colon mucosal epithelium, the lamina propria, the muscular layer and the submucosa glands of the rats in the blank group have clear and regular structures and are completely arranged, more goblet cells can be seen, and no obvious inflammation is seen. The colon mucosa layer of the 3% acetic acid group has a complete intestinal epithelial structure, epithelial cells have normal morphological structure and are arranged closely, the inherent layer intestinal gland is rich, more goblet cells can be seen, and no obvious inflammation is seen. Mucosal layers in the 5% acetate group were mostly exfoliated by intestinal epithelial cells (black arrows); edema is visible in the local submucosa, with loose arrangement of connective tissue (black arrows); myofibroedema and cytopenia were seen in the local muscle layer, but more goblet cells were seen without significant inflammation. The yang-deficiency constipation model belongs to functional constipation, although pathological tissues of colon have epithelial cell shedding and local mucosal edema symptoms, the number of goblet cells is normal, and inflammation is not seen, which indicates that the yang-deficiency constipation model does not show obvious organic injury.
7. Secretion of mucus in colonic tissue: after the molding is finished, the average number of mucus secreting positive cells of the 3% acetic acid group and the 5% acetic acid group is remarkably reduced compared with that of the blank group, and the difference is statistically significant (P < 0.01). The results are shown in FIG. 4. Colonic mucus is a high molecular weight epithelial glycoprotein, and an immune barrier formed by the colonic mucus can resist the erosion of microorganisms and insoluble substances and provide protection for surface mucosa. The average number of mucus secreting positive cells in the model component is significantly reduced, so that the mucus layer on the mucosal surface is thinned or disappeared, the probability that colon epithelial cells of constipation rats are invaded by bacteria is increased, and the colon immune barrier is damaged.
Secondary, secondary symptom results
1. General observation of yang deficiency signs: the rats in the control group have bright hair color, ruddy paw tails, normal appetite, formed excrement, spindle shape, no abnormal characteristics and no death. The 3% acetic acid group rats had decreased body hair brightness, pale paw, decreased appetite, decreased activity, and different degrees of mental depression. The 5% acetic acid rats had decreased body hair brightness, withered and hard, pale paw, decreased appetite, hard feces, less lying and movement, and were listened to different degrees. Stool morphology is shown in figure 5. The results show that the constipation rats show obvious yang deficiency characteristics.
2. Weight gain variation curve: from the aspect of weight increment change, after modeling, the weight of rats in the 3% model group and the 5% model group is obviously reduced compared with that of the control group, but the weight is not statistically significant. The results are shown in FIG. 6. The results show that the modeling factor has no significant effect on the body weight of the constipation rats.
3. Autonomic activity capacity: after 21 days of molding, the number of erections and crossing grids was significantly reduced in the 3% and 5% acetic acid model groups compared to the blank group, and the difference was statistically significant (P < 0.05). The results are shown in Table 4. The results of the study showed that the rats with constipation had reduced ability to move autonomously.
Table 4 number of erections and crossing of the rats in each group in the open field experiment (± SD)
Note: p < 0.001, P < 0.01, P < 0.05 compared to the blank group.
4. Thymus index: after the molding is finished, the thymus index of the 3% acetic acid group and the thymus index of the 5% acetic acid group are obviously reduced compared with that of the blank group, and the difference has statistical significance (P < 0.05). The results are shown in FIG. 7. The thymus, an important central immune organ, contributes to the differentiation and maturation of T cells. The thymus index of the model group rats is low, which indicates that the astriction can cause the thymus atrophy of the rats and the immunity is reduced.
The measurement results of the main symptoms and the secondary symptoms of the experimental rats show that the yang-deficiency type constipation model constructed by acetic acid and activated carbon ice water can show obvious yang-deficiency symptoms and constipation symptoms. The successful construction of the model of constipation caused by yang deficiency is shown. In addition, no experimental animal died in example 1 of the present invention, and the survival curve is detailed in FIG. 8. In order to highlight and further verify the advantage of low fatality rate of the yang-deficiency constipation model constructed by the invention, a white vinegar-induced constipation rat model is used as a comparison experiment, and the construction method of the acetic acid-induced yang-deficiency constipation rat model is evaluated under the condition of consistent molding time.
Experimental example 1: establishment of white vinegar-induced yang-deficiency constipation rat animal model
Preparation of the reagent: commercial edible white vinegar (Shanxi mature vinegar factory, batch number: 20140513, total acidity greater than or equal to 6.0 degree), activated carbon powder (Fuchen chemical reagent Co., Ltd.)
Experimental animals: same as example 1
Animal grouping: 30 healthy male SD rats were randomly divided into a blank control group (n = 10) and a white vinegar model group (n = 20).
The molding method comprises the following steps: 5mL of Shanxi white vinegar is administrated to the rats for first time, and 3 mL of vinegar is administrated to the rats for later time according to the weight of 200 g. On the next day after vinegar administration, animals were administered 16.67 mol/L of activated charcoal ice water at 0 ℃ to the animals at a rate of 5 mL/200g body weight. And alternately molding the white vinegar and the activated carbon ice water in single or double days. The molding time was 35 days in total.
And (3) evaluating the survival rate: the survival of the experimental rats during the experiment was recorded and a survival curve was constructed. The results are shown in FIG. 9. The results show that the acetic acid-induced constipation rate in the rat model is only 50% in 35 days. In fig. 8, it is evident that the survival rate of the rat model constructed by the method of the present invention is 100% in 35 days of modeling, and none of the rats died, and it is evident that the mortality rate of the method of the present invention is very low and the reproducibility is good.
Claims (6)
1. A construction method of an animal model of yang-deficiency constipation is characterized by comprising the following steps: performing intragastric lavage on experimental animals by using 1% -8% v/v acetic acid solution and 5% -50% g/v activated carbon-containing ice-water mixture, wherein the specific administration method comprises the following steps: the first dosage of the acetic acid solution is 0.5-10.0 mL/piece, then the acetic acid solution is administered according to 0.5-10 mL/100g, after 0.5-8 hours, the ice-water mixture containing the activated carbon is administered according to 0.5-10 mL/100g per piece, the gastric lavage time of the ice-water mixture of the acetic acid solution and the activated carbon is 1-8 weeks, namely 7-56 days, and the gastric lavage is performed for 1-7 times per week;
when the experimental animal shows 5 items of the following (1) (2) (3) (4) (5) (6) (7) major symptoms and 3 items of the following (8) (9) (10) (11) minor symptoms, the construction of the rat animal model with yang-deficiency constipation is successful;
the main symptoms are: (1) the anal temperature decreases; (2) the number of the defecation grains is reduced within 12 hours; (3) the defecation time is prolonged; (4) a decrease in the rate of small bowel advancement; (5) the water content of the excrement is reduced; (6) epithelial cells in colon pathological tissues drop or local submucosal edema is seen, connective tissues are arranged loosely, but the intestinal glands in the inherent layer are rich, more goblet cells can be seen, and obvious inflammation is not seen; (7) decreased mucus secretion from the colon;
the secondary symptoms are: (8) the hair color of the rat becomes grey-dark and dull; (9) weight loss; (10) decreased autonomic activity; (11) a decline in thymus index; (12) the food intake is reduced.
2. The method for constructing an animal model of yang-deficiency constipation according to claim 1, wherein: the experimental animal is an SPF-grade healthy adult animal, and the adult animal is an SD rat or a Wistar rat.
3. The method for constructing an animal model of yang-deficiency constipation according to claim 1, wherein: the acetic acid solution is 3% v/v acetic acid solution and 5% v/v acetic acid solution, and the activated carbon in the activated carbon ice-water mixture is 20% g/v.
4. The method for constructing an animal model of yang-deficiency constipation according to claim 3, wherein: the acetic acid solution is 3% v/v acetic acid solution, the activated carbon in the activated carbon ice-water mixture is 20% g/v, and the specific administration method comprises the following steps: the rats are fed with 5 mL/3% v/v acetic acid solution of the first dose while eating normal diet, and are intragastrically fed with 3% v/v acetic acid solution of 1.5 mL/100g dose from the next day, and after 2 hours, each intragastrically fed with 2.5 mL/100g activated carbon ice-water mixture containing 20% g/v activated carbon is fed 3 times per week; for 35 consecutive days.
5. The method for constructing an animal model of yang-deficiency constipation according to claim 3, wherein: the acetic acid solution is a 5% v/v acetic acid solution, the activated carbon in the activated carbon ice-water mixture is 20% g/v, and the specific administration method comprises the following steps: rats were fed a first 5.0 mL/5% v/v acetic acid solution while on a normal diet, gavage the 5% v/v acetic acid solution at a dose of 1.5 mL/100g the following day, 2 hours later, each was gavaged with 2.5 mL/100g of an ice-water mixture containing 20% g/v activated charcoal, 3 times a week; for 35 consecutive days.
6. The method for constructing an animal model of yang-deficiency constipation according to claim 1, wherein: epithelial cells in pathological tissues of colon drop or local submucosal edema is seen, connective tissues are arranged loosely, muscle fiber edema is seen in local muscle layers, cytoplasm is loose and lightly stained, but intestinal glands in the lamina propria are abundant, more goblet cells are seen, and obvious inflammation is not seen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010685318.3A CN111758669B (en) | 2020-07-16 | 2020-07-16 | Construction method and application of animal model with yang-deficiency constipation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010685318.3A CN111758669B (en) | 2020-07-16 | 2020-07-16 | Construction method and application of animal model with yang-deficiency constipation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111758669A CN111758669A (en) | 2020-10-13 |
CN111758669B true CN111758669B (en) | 2021-09-28 |
Family
ID=72726917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010685318.3A Active CN111758669B (en) | 2020-07-16 | 2020-07-16 | Construction method and application of animal model with yang-deficiency constipation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111758669B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087937A2 (en) * | 2000-05-18 | 2001-11-22 | Incyte Genomics, Inc. | G-protein coupled receptors |
CN101411375A (en) * | 2008-11-19 | 2009-04-22 | 南方医科大学 | Cold tea for preventing and treating coprostasis type sub-health and preparation method thereof |
CN101579405A (en) * | 2008-05-14 | 2009-11-18 | 李西秦 | Traditional Chinese medicine for curing constipation and preparation method thereof |
-
2020
- 2020-07-16 CN CN202010685318.3A patent/CN111758669B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001087937A2 (en) * | 2000-05-18 | 2001-11-22 | Incyte Genomics, Inc. | G-protein coupled receptors |
CN101579405A (en) * | 2008-05-14 | 2009-11-18 | 李西秦 | Traditional Chinese medicine for curing constipation and preparation method thereof |
CN101411375A (en) * | 2008-11-19 | 2009-04-22 | 南方医科大学 | Cold tea for preventing and treating coprostasis type sub-health and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
SD大鼠阳虚便秘模型的建立及评价;彭成 等;《中国药理学通报》;20070331(第3期);第407-409页 * |
阳虚便秘大鼠模型的建立及评价;岳奇 等;《世界最新医学信息文摘》;20170606;第17卷(第45期);第143-145、153页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111758669A (en) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kang et al. | Konjaku flour reduces obesity in mice by modulating the composition of the gut microbiota | |
Zhang et al. | Gut microbiota and type 2 diabetes mellitus: Association, mechanism, and translational applications | |
Kato et al. | Association of low serum adiponectin levels with erosive esophagitis in men: an analysis of 2405 subjects undergoing physical check-ups | |
Li et al. | Radix Puerariae thomsonii polysaccharide (RPP) improves inflammation and lipid peroxidation in alcohol and high-fat diet mice by regulating gut microbiota | |
TWI636133B (en) | A lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory | |
CN110638843A (en) | Application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial inoculum, food and/or medicament | |
Chen et al. | Elucidating dosage-effect relationship of different efficacy of rhubarb in constipation model rats by factor analysis | |
CN115120695B (en) | Licorice probiotic composite preparation and application thereof in preventing or treating non-alcoholic fatty liver disease | |
TW201917206A (en) | A Lactobacillus plantarum, composition, culturing method and use of decrease uric acid, improvement of allergy and/or decrease blood sugar | |
LU502579B1 (en) | Bifidobacterium lactis for relieving constipation and application thereof | |
CN113786419A (en) | Application of lactobacillus plantarum LPJZ-658 in preparation of medicines for treating non-alcoholic fatty liver disease | |
CN113197921A (en) | Application of bifidobacterium lactis MN-Gup and microbial inoculum thereof in treating type 2 diabetes | |
Wang et al. | Sodium Humate alleviates Enterotoxigenic Escherichia coli-induced intestinal dysfunction via alteration of intestinal microbiota and metabolites in mice | |
CN111758669B (en) | Construction method and application of animal model with yang-deficiency constipation | |
Yang et al. | Deprivation of dietary fiber enhances susceptibility of piglets to lung immune stress | |
TW201917207A (en) | A Lactobacillus plantarum, composition, culturing method and use of decrease blood lipids, decrease function index, decrease uric acid and/or anti-inflammatory | |
CN101601743B (en) | Pharmaceutical composition for treating ulcerative colitis and preparation method thereof | |
CN1857453B (en) | Chinese medicine composition for treating ulcerative colitis and its preparing method | |
CN108739668B (en) | Method for establishing animal experiment model by combining spleen and stomach deficiency-cold type gastric ulcer disease and application | |
Chen et al. | Dietary soybeans worsen dextran sodium sulfate-induced colitis by disrupting intestinal ecology | |
Furuta | Emerging questions regarding eosinophil's role in the esophago-gastrointestinal tract | |
Jia et al. | Croton tiglium L. seeds ameliorate loperamide-induced constipation via regulating gastrointestinal hormones and gut microbiota before and after processing | |
CN107029084A (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Colon and rectum precancerous lesion and application | |
CN104042879A (en) | Traditional Chinese medicine granules for reversing precancerous lesions of chronic atrophic gastritis and preparation method thereof | |
CN111419858B (en) | New use of phenylethanoid glycosides compound magnolin A for improving gastrointestinal function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |